Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-14 · accession 0000875320-25-000095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-19 | 2025-02-14 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $463.46 | -2,293 | 67.9K | -3% | -$1.06M | |
| 2025-02-19 | 2025-02-18 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $455.06 | -244 | 67.7K | -0.4% | -$111.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-14 | F | D | 2,293 | $463.46 | 67,939 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-18 | S | D | 244 | $455.06 | 67,695 | D | — | — |